帕比司他可延长多发性骨髓瘤患者的无进展生存期

关键信息

在该项随机试验中，387例多发性骨髓瘤患者在硼替佐米联合地塞米松治疗基础上加用加口服泛去乙酰化酶抑制剂帕比司他（panobinostat），平均无进展生存期（PFS）增加了8.1~12个月（P<0.0001），总生存期数据尚未获得。 截至分析时点，对照组中位总生存期为30.4个月，帕比司他组中位总生存期为33.6个月。

基于上述结果，复发或复发难治性多发性骨髓瘤患者或能从帕比司他治疗中获益，不过仍需长期随访来评估帕比司他对总生存期的影响。

TAKE-HOME MESSAGE

The addition of the oral pan-deacetylase inhibitor panobinostat to bortezomib plus dexamethasone increased median progression-free survival from 8.1 months to 12.0 months in this randomized trial including 387 patients (P < .0001). Overall survival data are not yet mature. At the time of analysis, median overall survival in the panobinostat group was 33.6 months compared with 30.4 months in the control group.

Based on findings, patients with relapsed or relapsed and refractory multiple myeloma may benefit from the addition of panobinostat, but researchers suggest that studies with longer follow-up are needed to assess the effect on overall survival.

The Lancet Oncology

Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma: A Multicentre, Randomised, Double-Blind Phase 3 Trial

Lancet Oncol 2014 Sep 19;[EPub Ahead of Print], JF San-Miguel, VTM Hungria, S-S Yoon, M Beksac, MA Dimopoulos, A Elghandour, WW Jedrzejczak, A Günther, TN Nakorn, N Siritanaratkul, P Corradini, S Chuncharunee, J-J Lee, RL Schlossman, T Shelekhova, K Yong, D Tan, T Numbenjapon, JD Cavenagh, J Hou, R LeBlanc, H Nahi, L Qiu, H Salwender, S Pulini, P Moreau, K Warzocha, D White, J Bladé, WM Chen, J de la Rubia, P Gimsing, S Lonial, JL Kaufman, EM Ocio, L Veskovski, SK Sohn, M-C Wang, JH Lee, H Einsele, M Sopala, C Corrado, B-R Bengoudifa, F Binlich, PG Richardson

This abstract is available on the publisher's site.

Access this abstract now

Copyright © 2014 Elsevier Inc. All rights reserved.

独家授权，未经许可，请勿转载。